Yosr Zenzri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yosr Zenzri has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Amel Mezlini
Oncology Department, Salah Azaiez Institute, Tunis, Tunisia
10 shared publicationsYosra Yahyaoui
Salah Azaiez Inst, Med Oncol Dept, Tunis, Tunisia
7 shared publicationsMouna Ayadi
Institut Salah-Azaïz
5 shared publicationsAmina Mokrani
Medical Oncology Department, Salah Azaïez Institute, Tunisia
4 shared publicationsFeryel Letaief
Medical Oncology Department, Salah Azaiz Institute, Tunis, Tunisia
3 shared publicationsGhada Sahraoui
Pathology Department, Salah Azaiez Institute, El Manar University, Faculty Of Medicine Of Tunis, Tunis, Tunisia
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Elsevier in Urology Case Reports
- Vol. 69, 103636
Penile metastasis from urothelial carcinoma of the bladder: An exceptionally rare localization
- 30 September 2026
- Published by Elsevier in Urology Case Reports
- Vol. 69, 103636
Open AccessPenile metastasis from urothelial carcinoma of the bladder: An exceptionally rare localization
- Open Access
Sex-Specific Trends in Thyroid Cancer Incidence and Histological Patterns in Northern Tunisia: A Population-Based Study with Implications for Cancer Control and Prevention
Background: Thyroid cancer (TC) represents the most common endocrine malignancy worldwide, with incidence increasing rapidly across diverse geographic regions. However, population-based evidence from North Africa remains limited, and comprehensive longitudinal analyses examining sex-specific incidence patterns, histological subtypes, and trends in tumor extension are lacking in Tunisia. Aim: This study aimed to (i) quantify TC incidence trends by sex and age group, (ii) characterize histological subtype-specific temporal patterns and tumor extension at diagnosis in northern Tunisia between 2000 and 2018, and (iii) to address projections in incidence by sex until 2040. Methods: A retrospective, population-based registry study was conducted using data from the Northern Tunisia Cancer Registry (NTCR), covering 11 governorates with a population of 5,233,700 in 2018. All primary invasive TC cases diagnosed between 2000 and 2018 were included (n = 3639). Age-standardized incidence rates (ASIRs) were calculated using the WHO standard population. Temporal trends were assessed using Joinpoint regression to estimate average annual percentage change (AAPC) with 95% confidence intervals. Projections of TC incidence to 2040 were generated using Bayesian autoregressive age–period–cohort models. Results: TC incidence increased significantly between 2000 and 2018, with overall ASIR rising from 2.8 to 5.0 per 100,000 person-years (AAPC = 3.8%, p < 0.001). In males, ASIR increased from 0.9 to 2.4 (AAPC = 3.0%, p < 0.001), while in females it rose from 3.7 to 7.8 (AAPC = 4.3%, 95% CI: 3.0–5.7; p < 0.001). The increase was predominantly driven by papillary thyroid carcinoma (PTC) (AAPC = 6.4% in males; 5.8% in females; both p < 0.001), whereas follicular thyroid carcinoma (FTC) remained stable. Notably, the proportion of metastatic cases decreased significantly in females (AAPC = −7.2%, p = 0.033), and the proportion of regionally advanced disease decreased in males (AAPC = −5.0%, p = 0.034). Conclusions: This population-based study demonstrates a sustained rise in TC incidence in northern Tunisia, disproportionately affecting women and largely driven by papillary histology. The concurrent increase in TC incidence alongside a reduction in regional and metastatic extension at diagnosis occurred. These findings have important implications for cancer prevention and control, highlighting the need for risk-adapted screening strategies and rationalized diagnostic practices.
Open AccessSex-Specific Trends in Thyroid Cancer Incidence and Histological Patterns in Northern Tunisia: A Population-Based Study with Implications for Cancer Control and Prevention
Background: Thyroid cancer (TC) represents the most common endocrine malignancy worldwide, with incidence increasing rapidly across diverse geographic regions. However, population-based evidence from North Africa remains limited, and comprehensive longitudinal analyses examining sex-specific incidence patterns, histological subtypes, and trends in tumor extension are lacking in Tunisia. Aim: This study aimed to (i) quantify TC incidence trends by sex and age group, (ii) characterize histological subtype-specific temporal patterns and tumor extension at diagnosis in northern Tunisia between 2000 and 2018, and (iii) to address projections in incidence by sex until 2040. Methods: A retrospective, population-based registry study was conducted using data from the Northern Tunisia Cancer Registry (NTCR), covering 11 governorates with a population of 5,233,700 in 2018. All primary invasive TC cases diagnosed between 2000 and 2018 were included (n = 3639). Age-standardized incidence rates (ASIRs) were calculated using the WHO standard population. Temporal trends were assessed using Joinpoint regression to estimate average annual percentage change (AAPC) with 95% confidence intervals. Projections of TC incidence to 2040 were generated using Bayesian autoregressive age–period–cohort models. Results: TC incidence increased significantly between 2000 and 2018, with overall ASIR rising from 2.8 to 5.0 per 100,000 person-years (AAPC = 3.8%, p < 0.001). In males, ASIR increased from 0.9 to 2.4 (AAPC = 3.0%, p < 0.001), while in females it rose from 3.7 to 7.8 (AAPC = 4.3%, 95% CI: 3.0–5.7; p < 0.001). The increase was predominantly driven by papillary thyroid carcinoma (PTC) (AAPC = 6.4% in males; 5.8% in females; both p < 0.001), whereas follicular thyroid carcinoma (FTC) remained stable. Notably, the proportion of metastatic cases decreased significantly in females (AAPC = −7.2%, p = 0.033), and the proportion of regionally advanced disease decreased in males (AAPC = −5.0%, p = 0.034). Conclusions: This population-based study demonstrates a sustained rise in TC incidence in northern Tunisia, disproportionately affecting women and largely driven by papillary histology. The concurrent increase in TC incidence alongside a reduction in regional and metastatic extension at diagnosis occurred. These findings have important implications for cancer prevention and control, highlighting the need for risk-adapted screening strategies and rationalized diagnostic practices.
- Open Access
- 30 May 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 1-6
Soft tissue metastasis in colorectal cancer: a case report
Soft tissue metastases of solid tumors are rare events, especially for colorectal cancers. We report herein the case of a 65-year-old Arab woman with soft tissue metastases (left arm, right scapula, and right axillary masses) of a colorectal cancer 4 years after the initial surgery. The patient was treated with folinic acid–fluorouracil–irinotecan and bevacizumab as first-line treatment. One year after completion of chemotherapy, the patient remained alive. The key aim in reporting this case is to raise awareness among oncologists regarding potential unusual metastasis locations of colon adenocarcinoma such as skin and skeletal muscle.
- 30 May 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 1-6
Open AccessSoft tissue metastasis in colorectal cancer: a case report
Soft tissue metastases of solid tumors are rare events, especially for colorectal cancers. We report herein the case of a 65-year-old Arab woman with soft tissue metastases (left arm, right scapula, and right axillary masses) of a colorectal cancer 4 years after the initial surgery. The patient was treated with folinic acid–fluorouracil–irinotecan and bevacizumab as first-line treatment. One year after completion of chemotherapy, the patient remained alive. The key aim in reporting this case is to raise awareness among oncologists regarding potential unusual metastasis locations of colon adenocarcinoma such as skin and skeletal muscle.
- Open Access
- 19 December 2024
- Published by Wiley
Vitiligo like lesions induced by novel therapeutic drug ribociclib in metastatic breast cancer patients
Introduction:Cyclin dependent kinase (CDK) 4/6 inhibitors are oral drugs that include Abemaciclib, Ribociclib and Palbociclib. These drugs target the CDK4/6, that acts as a converging point for different growth proliferation and growth arrest signals in the cell cycle regulation. CDK 4/6 inhibitors block it, to cause cell growth arrest leading to tumor cell death. These drugs are only used for breast cancer that is hormone receptor positive, in association with an endocrine therapy that varies from anti estrogen, aromatase inhibitors and selective estrogen receptor modulator. Common side effects include hematological toxicity, QT elongation for Ribociclib and digestive toxicity for Abemaciclib. Less common side effects include cutaneous toxicity. In fact, vitiligo-like lesions have been described with the use of Ribociclib.
- 19 December 2024
- Published by Wiley
Open AccessVitiligo like lesions induced by novel therapeutic drug ribociclib in metastatic breast cancer patients
Introduction:Cyclin dependent kinase (CDK) 4/6 inhibitors are oral drugs that include Abemaciclib, Ribociclib and Palbociclib. These drugs target the CDK4/6, that acts as a converging point for different growth proliferation and growth arrest signals in the cell cycle regulation. CDK 4/6 inhibitors block it, to cause cell growth arrest leading to tumor cell death. These drugs are only used for breast cancer that is hormone receptor positive, in association with an endocrine therapy that varies from anti estrogen, aromatase inhibitors and selective estrogen receptor modulator. Common side effects include hematological toxicity, QT elongation for Ribociclib and digestive toxicity for Abemaciclib. Less common side effects include cutaneous toxicity. In fact, vitiligo-like lesions have been described with the use of Ribociclib.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 113 (C) , 108970
Primary adenocarcinoma of the upper esophagus
Introduction and importance: Cervical esophageal cancer is a rare condition, accounting for less than 5 % of all esophageal malignancies. Case presentation: We report here a case of a 65-year-old female patient with a history of breast cancer diagnosed in 1985 treated with surgery, adjuvant chemotherapy, and radiotherapy. This woman presented with chronic organic high dysphagia to both solid and liquids and food impaction. Gastroscopy showed a stenosing esophageal budding tumor located at 20 cm from the incisors. Histological examination showed a well-differentiated adenocarcinoma. Clinical discussion: The diagnosis of primary adenocarcinoma of the upper esophagus is based on a combination of clinical presentation, imaging studies, and confirmed by histopathological examination. Upper digestive endoscopy is the gold standard for the diagnosis of esophageal cancer. Conclusion: Primary adenocarcinoma of the upper esophagus is a rare form of esophageal cancer. Highlights:
- 1 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 113 (C) , 108970
Open AccessPrimary adenocarcinoma of the upper esophagus
Introduction and importance: Cervical esophageal cancer is a rare condition, accounting for less than 5 % of all esophageal malignancies. Case presentation: We report here a case of a 65-year-old female patient with a history of breast cancer diagnosed in 1985 treated with surgery, adjuvant chemotherapy, and radiotherapy. This woman presented with chronic organic high dysphagia to both solid and liquids and food impaction. Gastroscopy showed a stenosing esophageal budding tumor located at 20 cm from the incisors. Histological examination showed a well-differentiated adenocarcinoma. Clinical discussion: The diagnosis of primary adenocarcinoma of the upper esophagus is based on a combination of clinical presentation, imaging studies, and confirmed by histopathological examination. Upper digestive endoscopy is the gold standard for the diagnosis of esophageal cancer. Conclusion: Primary adenocarcinoma of the upper esophagus is a rare form of esophageal cancer. Highlights:
- Open Access
- 6 March 2023
- Published by Wiley
Subacute sensory neuropathy as a Paraneoplastic syndrome associated with an undifferentiated Lung carcinoma A case report
This report describes a case of anti-hu antibody associated paraneoplastic sensory neuropathy with an undifferentiated lung tumor . The aim of this case was to highlight the importance of a multidisciplinary team approach for early recognition and rapid treatment of paraneoplastic neurological syndromes
- 6 March 2023
- Published by Wiley
Open AccessSubacute sensory neuropathy as a Paraneoplastic syndrome associated with an undifferentiated Lung carcinoma A case report
This report describes a case of anti-hu antibody associated paraneoplastic sensory neuropathy with an undifferentiated lung tumor . The aim of this case was to highlight the importance of a multidisciplinary team approach for early recognition and rapid treatment of paraneoplastic neurological syndromes
- 3 July 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 38 (2) , 274-281
Clinico-Epidemiological Profile, Prognostic Factors and Treatment Outcome of Refractory Hodgkin Lymphoma
Approximately 5–10% of patients with Hodgkin lymphoma are refractory to initial treatment. The aim of our study was to assess the clinico-epidemiological profile, prognostic factors and treatment outcome. A retrospective study was conducted over a period of 12 years between June 2006 and January 2018 at the oncology department of Salah Azaïz Institute. Thirty-one patients were included. The median age was 27 years with a female predominance (sex ratio = 0.93).The majority had an advanced stage (61%). IGEV regimen was the most commonly used salvage chemotherapy (n = 14). Age above 30 years was predictive of treatment failure after salvage therapy (p = 0.003). IGEV regimen showed better results than ICE protocol in terms of response to salvage therapy (p = 0.048). Seven patients had salvage radiotherapy. Four patients had autologous stem cell transplant. Progressive disease (n = 12) was the main cause of non-eligibility of autologous stem cell tansplant. Overall survival and progression free survival at 3 years were 50% and 5% respectively. The prognostic factors influencing the overall survival were age above 30 years (p = 0.001), advanced Ann Arbor stage before progression (p = 0.02), advanced Ann Arbor stage of refractory Hodgkin lymphoma (p = 0.001), histological subtype (p = 0.001), CD20 expression (p = 0.027) and non-response to salvage therapy (p = 0.004). The prognostic factor influencing progression free survival was the non-response to salvage therapy (p = 0.045). The prognosis of refractory Hodgkin lymphoma remains poor. The current standard secondary treatment consists of combination therapy, usually followed by autologous stem cell transplantat. Innovative therapies are needed to improve the prognosis of refractory Hodgkin lymphoma.
- 3 July 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 38 (2) , 274-281
Clinico-Epidemiological Profile, Prognostic Factors and Treatment Outcome of Refractory Hodgkin Lymphoma
Approximately 5–10% of patients with Hodgkin lymphoma are refractory to initial treatment. The aim of our study was to assess the clinico-epidemiological profile, prognostic factors and treatment outcome. A retrospective study was conducted over a period of 12 years between June 2006 and January 2018 at the oncology department of Salah Azaïz Institute. Thirty-one patients were included. The median age was 27 years with a female predominance (sex ratio = 0.93).The majority had an advanced stage (61%). IGEV regimen was the most commonly used salvage chemotherapy (n = 14). Age above 30 years was predictive of treatment failure after salvage therapy (p = 0.003). IGEV regimen showed better results than ICE protocol in terms of response to salvage therapy (p = 0.048). Seven patients had salvage radiotherapy. Four patients had autologous stem cell transplant. Progressive disease (n = 12) was the main cause of non-eligibility of autologous stem cell tansplant. Overall survival and progression free survival at 3 years were 50% and 5% respectively. The prognostic factors influencing the overall survival were age above 30 years (p = 0.001), advanced Ann Arbor stage before progression (p = 0.02), advanced Ann Arbor stage of refractory Hodgkin lymphoma (p = 0.001), histological subtype (p = 0.001), CD20 expression (p = 0.027) and non-response to salvage therapy (p = 0.004). The prognostic factor influencing progression free survival was the non-response to salvage therapy (p = 0.045). The prognosis of refractory Hodgkin lymphoma remains poor. The current standard secondary treatment consists of combination therapy, usually followed by autologous stem cell transplantat. Innovative therapies are needed to improve the prognosis of refractory Hodgkin lymphoma.
- Open Access
- 23 December 2020
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 37
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma: clinicopathological study and treatment outcome in 50 patients
The stomach is the most frequent site of extronodal lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade, B-cell neoplasm strongly associated with Helicobacter pylori (HP) infection. The presenting complaints of gastric MALT lymphoma are usually nonspecific. HP eradication is regarded as the first-line therapy in early stage disease. Management of patients who failed to achieve remission following HP eradication include chemotherapy, radiotherapy and in selected cases, surgery. The aim of the present study was to examine the clinical characteristics and treatment nutcome of natients with gastric MALT lymphoma.
- 23 December 2020
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 37
Open AccessGastric mucosa-associated lymphoid tissue (MALT) lymphoma: clinicopathological study and treatment outcome in 50 patients
The stomach is the most frequent site of extronodal lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade, B-cell neoplasm strongly associated with Helicobacter pylori (HP) infection. The presenting complaints of gastric MALT lymphoma are usually nonspecific. HP eradication is regarded as the first-line therapy in early stage disease. Management of patients who failed to achieve remission following HP eradication include chemotherapy, radiotherapy and in selected cases, surgery. The aim of the present study was to examine the clinical characteristics and treatment nutcome of natients with gastric MALT lymphoma.
- 6 October 2020
- Published by Wiley in The Breast Journal
- Vol. 27 (1) , 60-61
Diagnosis and treatment of synchronous breast and small bowel non‐Hodgkin’s lymphoma
- 6 October 2020
- Published by Wiley in The Breast Journal
- Vol. 27 (1) , 60-61
Diagnosis and treatment of synchronous breast and small bowel non‐Hodgkin’s lymphoma
- 13 August 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1732-1734
Suggestion of Tunisia’s medical oncologist in the management of breast cancer during COVID-19 pandemic
Cancer patients are at higher risk to be infected with COVID-19 and to develop a more severe form. Breast cancer (BC) treatments, including chemotherapy (CT), targeted therapy and immunotherapy can weaken the immune system and possibly cause lung problems. For all these reasons Salah Azaiez Institute's department of Medical Oncology took drastic actions to protect patients. In this article we will discuss protocol adjustments taken during the COVID-19 pandemic for breast cancer patients.
- 13 August 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (7) , 1732-1734
Suggestion of Tunisia’s medical oncologist in the management of breast cancer during COVID-19 pandemic
Cancer patients are at higher risk to be infected with COVID-19 and to develop a more severe form. Breast cancer (BC) treatments, including chemotherapy (CT), targeted therapy and immunotherapy can weaken the immune system and possibly cause lung problems. For all these reasons Salah Azaiez Institute's department of Medical Oncology took drastic actions to protect patients. In this article we will discuss protocol adjustments taken during the COVID-19 pandemic for breast cancer patients.